Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed a contract for pharmaceutical contract manufacturing worth approximately KRW 279.6B with a pharmaceutical company based in Europe.
📊 [Key Disclosure Details & Financial Figures]
- Contract Title: Pharmaceutical Contract Manufacturing Agreement
- Contract Amount: KRW 279,608,210,000 (USD 188,950,000)
- Applied Exchange Rate: USD/KRW 1,479.80 (Initial base rate on March 13, 2026)
- Recent Annual Revenue: KRW 4,547,322,176,421 (Based on 2024 consolidated financial statements)
- Contract Amount to Revenue Ratio: 6.15%
- Counterparty: Pharmaceutical company based in Europe (Counterparty name undisclosed due to business confidentiality)
- Contract Period: July 31, 2025 – March 13, 2032
- Contract Date: August 11, 2025
- Disclosure Postponement Period: March 13, 2032 (Scheduled date for counterparty disclosure)
- Other Important Matters:
- The contract was signed in August 2025, but was not disclosed at the time as it fell below the disclosure criteria threshold. On March 13, 2026, minimum purchase quantities were confirmed upon fulfilling contract terms, triggering this disclosure.
- The contract end date is subject to change upon mutual agreement.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Revenue and Earnings Recognition Following Minimum Quantity Confirmation
This disclosure was published as the minimum purchase quantities were confirmed following the fulfillment of contract terms.
Checking how the contract with confirmed minimum purchase quantities is recognized in actual revenue and earnings over the contract period is crucial for understanding its financial impact on the company.
Relevant developments can be verified in upcoming periodic reports and relevant follow-up disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
